KR920003968A - 염증성 장 질환의 치료방법 - Google Patents

염증성 장 질환의 치료방법 Download PDF

Info

Publication number
KR920003968A
KR920003968A KR1019910014710A KR910014710A KR920003968A KR 920003968 A KR920003968 A KR 920003968A KR 1019910014710 A KR1019910014710 A KR 1019910014710A KR 910014710 A KR910014710 A KR 910014710A KR 920003968 A KR920003968 A KR 920003968A
Authority
KR
South Korea
Prior art keywords
alkyl
integer
independently hydrogen
treatment
inflammatory bowel
Prior art date
Application number
KR1019910014710A
Other languages
English (en)
Inventor
앤 페네타 질
Original Assignee
리로이 휘테커
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리로이 휘테커, 일라이 릴리 앤드 캄파니 filed Critical 리로이 휘테커
Publication of KR920003968A publication Critical patent/KR920003968A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

내용 없음

Description

염증성 장 질환의 치료방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (1)

  1. 염증성 장 질환 치료용 약물을 제조하기 위한 하기 일반식(Ⅰ)의 화합물 또는 그의 약학적으로 허용되는 염의 용도:
    상기식에서, R1및 R2는 각각 독립적으로 수소, C1-C6알킬, C1-C6-알콕시 또는 C1-C4알킬(C1-C4알킬)이고, R3및 R4는 각각 독립적으로 수소 또는 C1-C4알킬이며, n은 0내지 4의 정수이고, m은 0또는 1이며, 단, m 및 n이 둘다 0일수는 없고, R5및 R6는 하기 (A), (B) 및 (C)중의 하나의 정의된다. (A)R5및 R6은 각각 독립적으로 수소, C1-C8알킬,C3-C8사이클로알킬, C2-C8알케닐, C2-C8알키닐, -(CH2)qOR7, -(CH2)qN(R7R2), -(CH2)qSR7, -(CH2)r나프틸 또는
    이고, 여기서, q는 1내지 6의 정수이고, R7및 R8은 각각 독립적으로 수소 또는 C1-C4알킬이며, R9은 수소, 할로, C1-C4알킬,트리플루오로메틸, 하이드록시, 아미노, C1-C4알킬아미노, 디(C1-C4알킬)아미노, 페닐 아미노 또는 디페닐아미노이며, r은 0내지 4의 정수이거나, 또는 (B) R5및 R6중 하나는 상기(A)에서 정의한 바와 같고 다른 하나는 일반식
    (여기서, mα,nα,R1α,R2α,R3α및 R4a는 각각 m, n, R1, R2, R3및 R4와 동일한 치환체이다)의 그룹이거나, 또는 (C)R5및 R6는 그들이 결합된 질소원자와 함께 그룹,또는을 형성하고, 여기서 R4는 상기 정의한 바와 같으면, R10은 수소, C1-C4알킬,또는-(CH2)r-N(R7R8) (여기서, R7, R8, R9및 r은 상기 정의한 바와 같고 s 및 t는 각각 독립적으로 0 내지 4의 정수이다)이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910014710A 1990-08-27 1991-08-24 염증성 장 질환의 치료방법 KR920003968A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57228690A 1990-08-27 1990-08-27
US07/572,286 1990-08-27

Publications (1)

Publication Number Publication Date
KR920003968A true KR920003968A (ko) 1992-03-27

Family

ID=24287150

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910014710A KR920003968A (ko) 1990-08-27 1991-08-24 염증성 장 질환의 치료방법

Country Status (10)

Country Link
US (1) US5552439A (ko)
EP (1) EP0474403B1 (ko)
JP (1) JPH04230622A (ko)
KR (1) KR920003968A (ko)
AU (1) AU642762B2 (ko)
CA (1) CA2049481A1 (ko)
DE (1) DE69109583T2 (ko)
ES (1) ES2071930T3 (ko)
HU (1) HUT61661A (ko)
ZA (1) ZA916555B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4204405A1 (de) * 1991-08-02 1993-02-04 Boehringer Mannheim Gmbh Verwendung von di-tert.-butylhydroxyphenyl-derivaten zur therapie von entzuendlichen erkrankungen des magen-darm-traktes
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US5633283A (en) * 1995-01-23 1997-05-27 Eli Lilly And Company Method for treating multiple sclerosis
JP3299100B2 (ja) * 1995-12-05 2002-07-08 株式会社資生堂 フェニレンジアミン誘導体及びラジカルスカベンジャー、脳梗塞抑制剤、脳浮腫抑制剤
US6083989A (en) * 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
WO1999059569A1 (en) * 1998-05-19 1999-11-25 Centaur Pharmaceuticals, Inc. Benzamide therapeutics for the treatment of inflammatory bowel disease
AU1917201A (en) * 1999-11-18 2001-05-30 Centaur Pharmaceuticals, Inc. Amide therapeutics and methods for treating inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6689788B1 (en) 2000-08-25 2004-02-10 University Of Florida Method and composition for treatment of inflammatory bowel disease
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
IL152127A0 (en) * 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
AU2004314731B2 (en) 2004-01-20 2011-07-07 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
JP5154406B2 (ja) 2005-04-13 2013-02-27 アステックス、セラピューティックス、リミテッド 医薬化合物
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
EP2081891A2 (en) 2006-10-12 2009-07-29 Astex Therapeutics Limited Pharmaceutical compounds having hsp90 inhibitory or modulating activity
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
EP2073804B1 (en) 2006-10-12 2017-09-13 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in the treatment of pain
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US7923014B2 (en) * 2007-02-12 2011-04-12 The Board Of Regents Of The University Of Texas System Expression and purification of HIP/PAP and uses therefor
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
EP3215149A4 (en) 2014-11-06 2018-06-27 Northwestern University Inhibition of cancer cell motility
US10449198B2 (en) 2016-07-01 2019-10-22 The University Of Liverpool Method for treating pain

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043774A (en) * 1955-09-23 1962-07-10 Ethyl Corp Organic compositions
NL281258A (ko) * 1961-07-28 1900-01-01 United States Rubber Co
US3305483A (en) * 1964-12-03 1967-02-21 Ethyl Corp Stabilized organic compositions
US3809761A (en) * 1970-03-12 1974-05-07 Ethyl Corp Method for reducing plasma lipid levels
US3792170A (en) * 1972-03-14 1974-02-12 Merck & Co Inc Novel alkylsulfinyl derivatives for pain,fever and inflammation
DE2240609A1 (de) * 1972-08-18 1974-02-28 Hoechst Ag Stoffwechselwirksame derivate der 4-hydroxy-3,5-di-alkylphenyl-propionsaeure
US4073942A (en) * 1972-10-23 1978-02-14 Boehringer Ingelheim Gmbh Halo-substituted hydroxybenzyl-amines as secretolytic agents
GB1405767A (en) * 1972-12-14 1975-09-10 Ethyl Corp Method formulation and pharmaceutical composition for reducing plasma lipid levels
US3994828A (en) * 1973-06-07 1976-11-30 Dynapol Corporation Nonabsorbable antioxidant
US4116930A (en) * 1975-11-03 1978-09-26 Ciba-Geigy Corporation Pyromellitic dimiides of 3,5-dialkyl-4-hydroxyphenylsubstituted amines
US4128664A (en) * 1977-05-16 1978-12-05 Riker Laboratories, Inc. Substituted benzamides as anti-inflammatory agents
US4324717A (en) * 1980-06-23 1982-04-13 The B. F. Goodrich Company Norbornene polymers stabilized with hindered aromatic alcohols
US4562201A (en) * 1982-07-26 1985-12-31 American Hospital Supply Corporation Aminomethyl benzanilides
JPS6061523A (ja) * 1983-09-16 1985-04-09 Shionogi & Co Ltd 経口用ドブタミン製剤
US4532356A (en) * 1983-11-16 1985-07-30 Ethyl Corporation Chemical process
GB8501646D0 (en) * 1985-01-23 1985-02-27 Nipa Lab Ltd Control of micro-organisms
US4959503A (en) * 1986-04-11 1990-09-25 Warner-Lambert Company Diarylalkanoids having activity as lipoxygenase inhibitors
IT1204416B (it) * 1986-06-27 1989-03-01 Midy Spa Medicamenti a base di analoghi di feniletanolammine per il trattamento di disturbi gastro-intestinali ed uterini
US4708966A (en) * 1986-06-27 1987-11-24 The Procter & Gamble Company Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation
DE3702755A1 (de) * 1987-01-30 1988-08-11 Hoechst Ag 3,5-di-tert.-butyl-4-hydroxybenzoesaeureamid, verschiedene von dessen derivaten, verfahren zur herstellung dieser verbindungen, die sie enthaltenden arzneimittel und ihre verwendung
US4948813A (en) * 1987-11-30 1990-08-14 E. I. Du Pont De Nemours And Company Benzylketone phospholipase A2 inhibitors
DE3903989A1 (de) * 1989-02-10 1990-09-20 Basf Ag Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika
EP0385043A1 (en) * 1989-02-28 1990-09-05 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) New derivatives of 4-substituted piperazines

Also Published As

Publication number Publication date
ZA916555B (en) 1993-04-28
DE69109583D1 (de) 1995-06-14
HUT61661A (en) 1993-03-01
CA2049481A1 (en) 1992-02-28
DE69109583T2 (de) 1995-10-12
EP0474403A1 (en) 1992-03-11
JPH04230622A (ja) 1992-08-19
EP0474403B1 (en) 1995-05-10
ES2071930T3 (es) 1995-07-01
AU8278291A (en) 1992-03-05
HU912792D0 (en) 1992-01-28
US5552439A (en) 1996-09-03
AU642762B2 (en) 1993-10-28

Similar Documents

Publication Publication Date Title
KR920003968A (ko) 염증성 장 질환의 치료방법
KR910006200A (ko) 퀴논 유도체 및 약리학적 이용
KR890002198A (ko) 유기 규소 화합물
ATE10804T1 (de) Ein diphenylhydantoin-derivat enthaltende pharmazeutische zusammensetzung, verwendete derivate und ihre herstellung.
FI881950A0 (fi) Hyönteisten ja punkkien karkoitteet
GB1544872A (en) 4-hydroxyphenylalkanolamine derivatives and preparation thereof
KR920016089A (ko) 제i형 당뇨병의 치료방법
KR910019977A (ko) 카르바졸 화합물
KR930003908A (ko) 염증, 국소빈혈-유도된 세포의 손상 및 근디스트로피의 치료방법
NO177995C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 1,3-dioksanderivater
DE69103630D1 (de) Oxazolederivate, ihre herstellung und diese enthaltende pharmazeutischen zubereitungen.
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR860003247A (ko) 티아디아진 화합물 및 그 염의 제조방법
KR890009901A (ko) 3-히드록시-2-(4-메톡시페닐)-5-(2-메틸아미노에틸)-2,3-디히드로-5h-1,5- 벤조티아제핀-4-온 유도체, 그의 제조 및 치료에의 이용
KR920702685A (ko) 4,6-o- 히드록시포스포릴글루코사민 유도체
IT1131887B (it) Glicosidi antraciclinici
KR890008148A (ko) 새로운 세파로스포린 화합물 및 항균제
KR910005860A (ko) 항간질환성 조성물
KR930023031A (ko) 아졸 유도체를 함유하는 항아로마타제제
KR920008012A (ko) 트리아졸 유도체
OA09416A (fr) Nouveaux dérivés triéniques de structure chroménique, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
KR840001578A (ko) 9,10-치환된 2-메시틸이미노-3-알킬-3,4,6,7-테트라하이드로-2H-피리미도(6,1-a)이소퀴놀린-4-온의 제조방법
KR910002853A (ko) 도파민 효능제
FR2361364A1 (fr) Nouveaux derives d'azetidine
CA2097997A1 (en) Vitamin d compounds and method of preparing these compounds

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid